Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

摘要: Background CC chemokine receptor 5 antagonists are a new class of antiretroviral agents. Methods We conducted two double-blind, placebo-controlled, phase 3 studies — Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 with patients who had R5 human immunodeficiency virus type (HIV-1) only. They been treated or resistance to three antiretroviral-drug classes HIV-1 RNA levels more than 5000 copies per milliliter. The were randomly assigned one regimens consisting maraviroc once daily, twice placebo, each which included optimized background therapy (OBT) based on treatment history drug-resistance testing. Safety efficacy assessed after 48 weeks. Results A total 1049 received the study drug; mean baseline level was 72,400 milliliter, median CD4 cell count 169 cubic millim...